The Diabetic Nephropathy drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diabetic Nephropathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued products.

GlobalData tracks 65 drugs in development for Diabetic Nephropathy by 60 companies/universities/institutes. The top development phase for Diabetic Nephropathy is preclinical with 26 drugs in that stage. The Diabetic Nephropathy pipeline has 58 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Diabetic Nephropathy pipeline products market are: Scohia Pharma, Serodus and AstraZeneca.

The key targets in the Diabetic Nephropathy pipeline products market include Endothelin 1 Receptor (Endothelin A Receptor or EDNRA), Kelch Like ECH Associated Protein 1 (Cytosolic Inhibitor Of Nrf2 or Inrf2 or Kelch Like Protein 19 or KEAP1), and Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1).

The key mechanisms of action in the Diabetic Nephropathy pipeline product include Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Antagonist with four drugs in Phase II. The Diabetic Nephropathy pipeline products include eight routes of administration with the top ROA being Oral and eight key molecule types in the Diabetic Nephropathy pipeline products market including Small Molecule, and Synthetic Peptide.

Diabetic Nephropathy overview

Diabetic nephropathy is damage to the kidney occurring due to diabetes. It is characterized by albuminuria, a reduction in glomerular filtration rate (GFR), and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels, and smoking. This condition is managed by medication and dietary modification.

For a complete picture of Diabetic Nephropathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.